Drug use review (DUR) board.
In accordance with 42 C.F.R. 456.716, the medicaid agency establishes a drug use review (DUR) board.
(1) The DUR board:
(a) Includes health professionals who are actively practicing and licensed in the state of Washington and who have recognized knowledge and expertise in one or more of the following:
(i) The clinically appropriate prescribing of outpatient drugs;
(ii) The clinically appropriate dispensing and monitoring of outpatient drugs;
(iii) Drug use review, evaluation, and intervention; and
(iv) Medical quality assurance.
(b) Is made up of at least one-third but not more than fifty-one percent physicians, and at least one-third pharmacists.
(2) The agency may appoint members of the pharmacy and therapeutics committee established by the agency under chapter
182-50 WAC or other qualified individuals to serve as members of the DUR board.
(3) The DUR board meets periodically to:
(a) Advise the agency on drug use review activities;
(b) Review provider and patient profiles;
(c) Review scientific literature to establish evidence-based guidelines for the appropriate use of drugs, including the appropriate indications and dosing;
(d) Recommend adoption of standards and treatment guidelines for drug therapy;
(e) Recommend interventions targeted toward correcting drug therapy problems; and
(f) Produce an annual report.
(4) The agency has the authority to accept or reject the recommendations of the DUR board in accordance with 42 C.F.R. 456.716(c).
[Statutory Authority: RCW
41.05.021 and
41.05.160. WSR 16-01-046, § 182-530-4000, filed 12/9/15, effective 1/9/16. WSR 11-14-075, recodified as § 182-530-4000, filed 6/30/11, effective 7/1/11. Statutory Authority: RCW
74.04.050,
74.08.090,
74.09.530, and
74.09.700. WSR 07-20-049, § 388-530-4000, filed 9/26/07, effective 11/1/07.]